Mergers & Acquisitions ·
Xenetic Biosciences proposes $162M share exchange with Santersus AG
XBIOXenetic Biosciences, Inc.
Xenetic Biosciences, Inc. filed an 8-K to furnish an updated investor presentation regarding its pending share exchange transaction with Santersus AG. The proposed acquisition values Xenetic at $21 million and Santersus at $141 million, resulting in a combined entity valued at approximately $162 million. Pre-merger Santersus shareholders are expected to own roughly 85% of the combined company, while existing Xenetic stockholders will hold about 15%. The transaction is anticipated to close in the fourth quarter of 2026, with the combined company trading on Nasdaq under the ticker symbol "SNTS." Santersus will operate as a wholly owned subsidiary focusing on NET-targeted therapies for immune-driven diseases and cancer. Xenetic Biosciences, Inc. operates in the biotechnology industry, developing targeted therapies for immune-driven diseases.